| pubmed-article:12501129 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:12501129 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:12501129 | lifeskim:mentions | umls-concept:C0205466 | lld:lifeskim |
| pubmed-article:12501129 | lifeskim:mentions | umls-concept:C0032105 | lld:lifeskim |
| pubmed-article:12501129 | lifeskim:mentions | umls-concept:C0132326 | lld:lifeskim |
| pubmed-article:12501129 | lifeskim:mentions | umls-concept:C0441889 | lld:lifeskim |
| pubmed-article:12501129 | lifeskim:mentions | umls-concept:C0442805 | lld:lifeskim |
| pubmed-article:12501129 | lifeskim:mentions | umls-concept:C0231174 | lld:lifeskim |
| pubmed-article:12501129 | lifeskim:mentions | umls-concept:C0205197 | lld:lifeskim |
| pubmed-article:12501129 | lifeskim:mentions | umls-concept:C1524003 | lld:lifeskim |
| pubmed-article:12501129 | lifeskim:mentions | umls-concept:C0301625 | lld:lifeskim |
| pubmed-article:12501129 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:12501129 | pubmed:dateCreated | 2002-12-25 | lld:pubmed |
| pubmed-article:12501129 | pubmed:abstractText | Patients on two nucleoside analogs plus nevirapine (NVP) who show low-level plasma HIV RNA might have insufficient NVP plasma levels and therefore might benefit from an increase in NVP dosing. | lld:pubmed |
| pubmed-article:12501129 | pubmed:language | eng | lld:pubmed |
| pubmed-article:12501129 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12501129 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:12501129 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12501129 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12501129 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:12501129 | pubmed:issn | 1528-4336 | lld:pubmed |
| pubmed-article:12501129 | pubmed:author | pubmed-author:SorianoVincen... | lld:pubmed |
| pubmed-article:12501129 | pubmed:author | pubmed-author:González-Laho... | lld:pubmed |
| pubmed-article:12501129 | pubmed:author | pubmed-author:NúñezMarinaM | lld:pubmed |
| pubmed-article:12501129 | pubmed:author | pubmed-author:Jiménez-Náche... | lld:pubmed |
| pubmed-article:12501129 | pubmed:author | pubmed-author:GallegoOscarO | lld:pubmed |
| pubmed-article:12501129 | pubmed:author | pubmed-author:de... | lld:pubmed |
| pubmed-article:12501129 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:12501129 | pubmed:volume | 3 | lld:pubmed |
| pubmed-article:12501129 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:12501129 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:12501129 | pubmed:pagination | 463-7 | lld:pubmed |
| pubmed-article:12501129 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:12501129 | pubmed:meshHeading | pubmed-meshheading:12501129... | lld:pubmed |
| pubmed-article:12501129 | pubmed:meshHeading | pubmed-meshheading:12501129... | lld:pubmed |
| pubmed-article:12501129 | pubmed:meshHeading | pubmed-meshheading:12501129... | lld:pubmed |
| pubmed-article:12501129 | pubmed:meshHeading | pubmed-meshheading:12501129... | lld:pubmed |
| pubmed-article:12501129 | pubmed:meshHeading | pubmed-meshheading:12501129... | lld:pubmed |
| pubmed-article:12501129 | pubmed:meshHeading | pubmed-meshheading:12501129... | lld:pubmed |
| pubmed-article:12501129 | pubmed:meshHeading | pubmed-meshheading:12501129... | lld:pubmed |
| pubmed-article:12501129 | pubmed:meshHeading | pubmed-meshheading:12501129... | lld:pubmed |
| pubmed-article:12501129 | pubmed:meshHeading | pubmed-meshheading:12501129... | lld:pubmed |
| pubmed-article:12501129 | pubmed:meshHeading | pubmed-meshheading:12501129... | lld:pubmed |
| pubmed-article:12501129 | pubmed:meshHeading | pubmed-meshheading:12501129... | lld:pubmed |
| pubmed-article:12501129 | pubmed:meshHeading | pubmed-meshheading:12501129... | lld:pubmed |
| pubmed-article:12501129 | pubmed:meshHeading | pubmed-meshheading:12501129... | lld:pubmed |
| pubmed-article:12501129 | pubmed:meshHeading | pubmed-meshheading:12501129... | lld:pubmed |
| pubmed-article:12501129 | pubmed:meshHeading | pubmed-meshheading:12501129... | lld:pubmed |
| pubmed-article:12501129 | pubmed:articleTitle | Does an increase in nevirapine plasma levels cause complete virologic suppression in patients experiencing early virologic failure? | lld:pubmed |
| pubmed-article:12501129 | pubmed:affiliation | Service of Pharmacy, Instituto de Salud Carlos III, Madrid, Spain. | lld:pubmed |
| pubmed-article:12501129 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:12501129 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:12501129 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:12501129 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
